Alaunos Therapeutics Inc (TCRT)
Alaunos Therapeutics, Inc. is a biotechnology company listed on NASDAQ as common stock under the ticker TCRT. The company is described as a clinical-stage oncology-focused cell therapy business, while its research also extends to small molecules for obesity and other metabolic disorders. Its development work includes an oral obesity compound designed to address limitations associated with injectable GLP-1 receptor agonists, with an emphasis on preserving lean muscle mass. Alaunos also evaluates ALN1001 and related derivatives in studies involving lipid deposition and gene expression. In addition, the company is developing the hunTR TCR discovery platform to target driver mutations. Founded in 2003, Alaunos Therapeutics is headquartered in Houston, Texas.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TCRT
|
$1.29
|
-6.0% Downside
|
Fair
|
Not available
|
Not available
|
Weak
|
0.0%
|
November 13, 2026
|
5.2x
|
1,134.7x
|
3.252 M
|
3.28 M
|
0.0%
|
78.0%
|
-862.4
|
68.6%
|
